Oncology Clinical Pathways Plasma Cell Disorders

April 2024 - V2.2024







Table of Contents

Presumptive Conditions	3
Monoclonal Gammopathies	4
Monoclonal Gammopathy of Undetermined Significance (MGUS)	5
<u>Plasmacytoma</u>	6
Smoldering Myeloma.	
Multiple Myeloma, First Line	8
Multiple Myeloma, Second Line Relapsed	9
Multiple Myeloma, Multiply Relapsed	10
Systemic AL Amyloidosis	11
Molecular Testing Table	12







<u>Plasma Cell Disorders – Presumptive Conditions</u>

VA automatically presumes that certain disabilities were caused by military service. This is because of the unique circumstances of a specific Veteran's military service. If a presumed condition is diagnosed in a Veteran within a certain group, they can be awarded disability compensation.

<u>Atomic Veterans – Exposure to Ionizing Radiation</u>

Multiple myeloma

<u>Vietnam Veterans – Agent Orange Exposure or Specified Locations</u>

- Monoclonal gammopathy of undetermined significance (MGUS)
- AL Amyloidosis


For more information, please visit <u>U.S. Department of Veterans Affairs - Presumptive Disability Benefits (va.gov)</u>







<u>Plasma Cell Disorders – Monoclonal Gammopathies</u>



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov

^a Consider Additional Lab Tests including quantitative immunoglobulins, UPEP with IFE depending on the clinical scenario; consider cross-sectional imaging for IgM monoclonal gammopathy

b High Risk based on risk stratification models that incorporate M-spike level and involved immunoglobulin

^c **Ancillary Testing** includes myeloma FISH panel, karyotype, and flow cytometry; myeloma FISH panel should include at minimum: 17p (TP53), del 13, 1q21, 1p, and t(11;14); also either upfront or reflex testing for t(4:14), t(14:16), and t(14:20)

^d Imaging PET/CT vertex to toes, whole body MRI, or whole body low-dose non-contrast CT

SPEP Serum Protein Electrophoresis

IFE Immunofixation Electrophoresis

SFLC Serum Free Light Chain

CBC Complete Blood Count

UPEP Urine Protein Electrophoresis


MGUS Monoclonal Gammopathy of Undetermined Significance







Plasma Cell Disorders - MGUS



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov

- ^a Risk Stratification based on involved immunoglobulin and level of monoclonal protein
- ^b Follow Up with Labs measurement of monoclonal protein (e.g. SPEP, SFLC, quantitative immunoglobulins), CBC, and chemistries (including SCr and Ca)
- ^c Monitoring if expected life expectancy is <5 years, consider discontinuing monitoring
- ^d **Ancillary Testing** includes myeloma FISH panel, karyotype, and flow cytometry; myeloma FISH panel should include at minimum: 17p (TP53), del 13, 1q21, 1p, and t(11;14); also either upfront or reflex testing for t(4;14), t(14;16), and t(14;20)
- elmaging PET/CT vertex to toes, whole body MRI, or whole body low-dose non-contrast CT

MGUS Monoclonal Gammopathy of Undetermined Significance

SPEP Serum Protein Electrophoresis

SFLC Serum Free Light Chain


CBC Complete Blood Count







Plasma Cell Disorders - Plasmacytoma



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov

a Imaging PET/CT, whole body MRI, or whole body non-contrast CT

^b Consider Additional Lab Tests including quantitative immunoglobulins, UPEP, and IFE depending on the clinical scenario

Exadiation if solitary plasmacytoma of bone is less ≤ 5cm dose with 35-40Gy; if > 5cm 40-50Gy; if solitary extramedullary plasmacytoma dose 40-50Gy regardless of size

Monitoring assess response with imaging after completion of radiation; SPEP with IFE, SFLC, CBC, and chemistries (including creatinine, calcium, albumin, and total protein)

SPEP Serum Protein Electrophoresis IFE Immunofixation Electrophoresis SFLC Serum Free Light Chain **CBC** Complete Blood Count


UPEP Urine Protein Electrophoresis







<u>Plasma Cell Disorders – Smoldering Myeloma</u>



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov

a Risk Stratification high risk defined as bone marrow plasma cells >20%, monoclonal protein >2 g/dL, and SFLC ratio >20 (involved/uninvolved light chain)

^b Follow Up with Labs measurement of monoclonal protein (e.g. SPEP, SFLC, quantitative immunoglobulins), CBC, and chemistries (including SCr and Ca)

ELenalidomide thromboembolism prophylaxis required; monitor for toxicity and response; reduce dose based on kidney function

d Consider Additional Lab Tests including quantitative immunoglobulins, UPEP, and IFE depending on the clinical scenario; consider yearly cross-sectional imaging (e.g. PET/CT vertex to toes, whole body MRI, or whole body low-dose non-contrast CT)

Monitoring if expected life expectancy is <5 years, consider discontinuing monitoring

fimaging PET/CT vertex to toes, whole body MRI, or whole body low-dose non-contrast CT

g Improvement or Stabilization of Multiple Myeloma Paraprotein based on SPEP, SFLC, UPEP, quantitative immunoglobulins

Ancillary Testing includes myeloma FISH panel, karyotype, and flow cytometry; myeloma FISH panel should include at minimum: 17p (TP53), del 13, 1q21, 1p, and t(11;14); also either upfront or reflex testing for t(4;14), t(14;16), and t(14;20)


SPEP Serum Protein Electrophoresis SFLC Serum Free Light Chain CBC Complete Blood Count IFE Immunofixation Electrophoresis UPEP Urine Protein Electrophoresis







<u>Plasma Cell Disorders – Multiple Myeloma, First Line</u>



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov

*Multiple Myeloma bone marrow biopsy for diagnosis required; consider Congo Red if amyloidosis is clinically or histologically suspected; consider CD138 immunohistochemistry for suboptimal BM aspirate or apparent discordance between aspirate smear and core biopsy

bone Protective Agent dental evaluation and serum calcium with vitamin D level required before initiation; assess kidney function; preferred agent is zoledronic acid (if CrCl < 30 ml/min, use denosumab or pamidronate)

Fisk Assessment by R-ISS (B2M, LDH, myeloma FISH, and albumin); if not already complete, obtain CBC, chemistries (including SCr and Ca), cross sectional imaging (PET/CT, whole body MRI, or whole non-contrast CT), measure of monoclonal protein (SPEP, SFLC, Quantitative immunoglobulins, and/or UPEP); myeloma FISH panel should include at minimum: 17p (TP53), del 13 1q21, 1p, and t(11;14); also either upfront or reflex testing for t(4;14), t(14;16), and t(14;20)

^d Transplant Eligibility discuss with transplant team if needed; discourage use of tobacco, alcohol, or illicit drugs

Grade 2 Neuropathy moderate symptoms or limiting instrumental ADLs

KRd check transthoracic echocardiogram prior to therapy initiation; do not use for patients with congestive heart failure or active coronary artery disease; consider DOAC for thromboprophylaxis due to higher risk of VTE with Carfilzomib based therapy

⁹ Assessment of Response includes SPEP, SFLC, and/or UPEP as appropriate; assessment of toxicity includes assessing cytopenias, neuropathy, VTE, infections

h RVd or KRd thromboprophylaxis and VZV prophylaxis required; consider PJP prophylaxis; consider dose reduction of lenalidomide based on renal function; consider dose reduction of dexamethasone based on age

Transplant early referral recommended; transplant team; referral recommended; transplant team; post-transplant team; post-transplant team; post-transplant team; post-transplant team; referral for cellular therapy (stem cell transplant, CAR T cell therapy) requires pre-transplant evaluation and review through TRACER

Proteosome Inhibitor preferred agent is bortezomib; monitor for neuropathy and dose reduce or discontinue proteosome inhibitor for worsening neuropath

k Improvement or Stabilization of Multiple Myeloma Paraprotein based on SPEP, SFLC, UPEP, quantitative immunoglobulins

VCd or RVd consider weekly bortezomib and subcutaneous administration of bortezomib to reduce neuropathy

Cyclophosphamide, bortezomib, dexamethasone is an option if renal function prohibits lenalidomide use; if renal function improves, switching to a lenalidomide-containing regimen is encouraged

"DRd thromboprophylaxis and VZV prophylaxis required; consider PJP prophylaxis. Hepatitis B serology, T&S and antibody screen required prior to initiation; consider dose reduction of lenalidomide based on renal function; consider dose reduction of dexamethasone based on age; daratumumab can affect quantification of SPEP M-spike


B2M Serum Beta-2 Microglobulin DOAC Direct Oral Anticoagulant MM Multiple Myeloma SPEP Serum Protein Electrophoresis SFLC Serum Free Light Chain T&S Type and Screen VTF Verpus Thromboembolism







<u>Plasma Cell Disorders – Multiple Myeloma, Second Line Relapsed</u>



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov

a Supportive Care supportive care should be provided to all myeloma patients receiving therapy

Subsequent Therapy consider the following when selecting subsequent therapy:

- Triplet therapy is usually considered more effective than doublet therapy
- CD38 antibody based therapy regimens should be considered if not previously administered

not bortezomib refractory

Alternate combination of drug classes or alternate drugs within a class when selecting a new treatment regimen (i.e., immunomodulatory agents, proteosome inhibitors, CD38 antibodies, alkylator chemotherapy, and others) Route and frequency of administration of new treatment regimens to alique with palent preferences in therapy.

Did last

anti-CD38

Dose reduction may be needed to continue therapy in the face of adverse events and prior toxicities

Consideration of Alternate Treatment based on duration and/or depth of response to prior therapy and toxicities

Assessment of Response includes SPEP, SFLC, and/or UPEP as appropriate; assessment of toxicity includes assessing cytopenias, neuropathy, VTE, infections

Treat Until Intolerance or Progression consider reduction or elimination of dexamethasone for patients responding well to therapy after at least six cycles

Assess patient comorbidities, multiple myeloma predictive/prognostic factors, and patient preference

Patient Comorbidities neuropathy: avoid bortezomib, cardiopulmonary disease: avoid cardilzomib Multiple Myeloma Predictive/Prognostic Factors: high risk cytogenetics: favor bortezomib or cardilzomib based regimens, presence of It(11;14): consider venetoclax based regimen; Patient Preference: consider regimens that are administered only in clinic depending on patient preference

Initiate therapy with lenalidomide, bortezomib, and dexamethasone (RVd) or bortezomib, cyclophosphamide, and dexamethasone (VCd) of g

Initiate therapy with daratumumab-hyaluronidase, lenalidomide, and dexamethasone (DRd) or daratumumab-hyaluronidase, bortezomib, and dexamethasone (DVd) of g

Referral for Cellular Therapy (stem cell transplant, CAR T cell therapy) requires pre-transplant evaluation and review through TRACER

De-Escalation of frequency or dose of dexamethasone is often performed to reduce side effects of long-term dexamethasone use; de-escalation of other components of therapy typically occur for side effects, in order to maintain duration of therapy

Supportive Care and Treatment Modification Consideration


- Thromboprophylaxis required with IMIDs (e.g., lenalidomide, pomalidomide); options include aspirin, enoxaparin, or DOAC; DOAC preferred when IMID is paired with Carfilzomib due to higher thrombosis risk
- VZV prophylaxis is required with proteosome inhibitors (e.g., bortezomib, carfilzomib) and with CD38 antibodies (e.g., daratumumab)
- PJP prophylaxis recommended due to ongoing/chronic dexamethasone use.
- Lenalidomide requires dose reduction/modification based on renal function
- Dexamethasone should be dose reduced to 20 mg weekly for age >75 years
- Once multiple myeloma response has been reached, dexamethasone dosing frequency should be reduced or even discontinued to reduce risk of infections
- Once manage management associated as the control of the control of
- Subcutaneous daratumumab-hyaluronidase is preferred over daratumumab due to reduced adverse reactions and faster administration
- T&S and antibody screen and hepatitis B serologies prior to daratumumab or daratumumab-hyaluronidase administration
- Palliative XRT for painful osseous lesions; minimize bone marrow exposure, especially of the pelvis, in patients who are transplant candidates
- Consider IVIG for patients with hypogammaglobulinemia of the uninvolved immunoglobulins and recurrent infections







<u>Plasma Cell Disorders – Multiple Myeloma, Multiply Relapsed</u>



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov

- ^a Supportive Care supportive care should be continued for all myeloma patients receiving therapy; referral to palliative care recommended; review molecular testing from last bone marrow biopsy; consider evaluating for BRAF V600E mutation in last bone marrow biopsy for consideration of BRAF/MEK targeted therapy, an emerging treatment option
- ^b Penta-Refractory or Triple-Class Refractory penta-refractory defined as progression within 6 months of therapy of each of the following therapies: lenalidomide, pomalidomide, bortezomib, carfilzomib, and anti-CD38 antibody (e.g. daratumumab); triple-class refractory defined as progression within 6 months of therapy with immunodulator, proteosome inhibitor, and anti-CD38 antibody
- ^c CAR T Cell Therapy is associated with risk of cytokine release syndrome and neurotoxicity, and requires inpatient hospitalization for monitoring
- d Referral for Cellular Therapy (stem cell transplant, CAR T cell therapy) requires pre-transplant evaluation and review through TRACER
- e Venetoclax requires TLS monitoring during ramp-up period and is associated with risk of infections; anti-viral prophylaxis is highly recommended; growth factor support may be used for cytopenias
- ^f Teclistamab requires facility support and protocols for monitoring of and management of cytokine release syndrome and CNS toxicity
- g Selinexor has moderate to high emetogenicity risk, can cause fatigue and hyponatremia; anti-emetic prophylaxis and close monitoring recommended; dose reduction frequently used to improve tolerability and duration of response


BCMA B-Cell Maturation Antigen
CAR T Chimeric Antigen Receptor T-cell







Plasma Cell Disorders - Systemic AL Amyloidosis



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email <u>CancerClinicalTrialsNavigation@va.gov</u>.

^a Systemic AL Amyloidosis pathway does not apply to other forms of amyloidosis, including TTR and AA amyloidosis; diagnosis of AL amyloidosis requires biopsy of the affected organ with congo red staining and mass spectroscopy demonstrating light chain and amyloid deposition; fat pad biopsy can be helpful if biopsy of affected organ is dangerous, impossible, or non-diagnostic

b Workup includes evaluation of affected organs as directed by symptoms (e.g., rerive or Gl involvement) and including evaluation for kidney impairment, nephrotic range proteinuria (e.g., urine protein/creatinine ratio or 24 hour urine collection), cardiac involvement (e.g., transthoracic echocardiogram and/or cardiac MRI, BNP, troponin I), and evaluation for bone marrow involvement/multiple myeloma including molecular testing (see initial multiple myeloma pathway)

Transplant referral for stem cell transplant requires pre-transplant evaluation and review through TRACER







<u>Plasma Cell Disorders – Molecular Testing Table</u>

Eligibility	Test Category	Test Type	Recommended Vendors	NPOP Coverage	Specimen Type
Patients who have had a bone marrow biopsy to work up a plasma cell disorder, including: 1.) Monoclonal Gammopathies of Undetermined Significance (MGUS) 2.) Plasmacytoma	FISH	FISH panel should be performed on CD138-sorted cells and include 17p (TP53), del 13, 1q21, 1p, and t(11;14). Additional upfront or reflex testing for t(4;14), t(14;16), and t(14;20)	Local VA or locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood
3.) Smoldering Myeloma4.) Multiple Myeloma - First Line (and second line if not performed earlier)	Flow cytometry	Flow cytometry	Local VA or locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood
	Karyotyping	Karyotyping	Local VA or locally contracted vendor	No	Bone Marrow Biopsy, Lymph Node Biopsy, Blood





